Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.39 |
| ▸ | SCN1A | P35498 | 2/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | MC3R | P41968 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8396114 | 0.85 | ALDH1A1 (0.40) | ALDH1A1HTTMAPTLMNASCN3A | |
| SCHEMBL8393467 | 0.85 | ALDH1A1 (0.42) | ALDH1A1HTTPOLBMAPTLMNA | |
| SCHEMBL8398430 | 0.84 | CA1 (0.43) | ALDH1A1HTTMAPTLMNASCN3A | |
| SCHEMBL7174642 | 0.82 | KDM4E (0.43) | ALDH1A1HTTMAPTLMNAMEN1 | |
| SCHEMBL1232491 | 0.80 | MAPT (0.58) | ALDH1A1HTTPOLBMAPTLMNA | |
| SCHEMBL7174644 | 0.79 | ALDH1A1 (0.39) | ALDH1A1HTTPOLBMAPTLMNA | |
| SCHEMBL6243924 | 0.77 | ALDH1A1 (0.68) | ALDH1A1MAPTLMNASCN3AMEN1 | |
| SCHEMBL8398451 | 0.76 | TERT (0.45) | TERTALDH1A1HTTPOLBMAPT | |
| SCHEMBL10676572 | 0.74 | ALDH1A1 (0.62) | ALDH1A1POLBMAPTLMNAMEN1 | |
| SCHEMBL6259358 | 0.74 | ALDH1A1 (0.51) | ALDH1A1HTTPOLBMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6166085-A | Method of producing analgesia | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-12-26 | — | — | US | claimed |
| EP-0915834-A1 | METHOD AND COMPOSITIONS FOR PRODUCING ANALGESIA | ELAN PHARMACEUTICALS, INC. (US) | 1999-05-19 | — | — | EP | claimed |
| WO-1998010759-A1 | METHOD OF PRODUCING ANALGESIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-03-19 | — | — | WO | claimed |
| WO-1997033860-A1 | METHOD AND COMPOSITIONS FOR PRODUCING ANALGESIA | NEUREX CORPORATION (US) | 1997-09-18 | — | — | WO | claimed |
| EP-3485881-B1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | HARVARD COLLEGE (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-06-01 | — | — | US | disclosed |
| US-20030040028-A1 | Analgesic screening method and composition | MILLER JAMES L (US) | 2003-02-27 | — | — | US | disclosed |
| US-6489119-B1 | SELECTING ANALGESIC AGENTS BASED ON THEIR SELECTIVE ABILITY TO BLOCK TETRODOTOXIN-INSENSITIVE SODIUM CHANNELS, PARTICULARLY IN COMPARISON TO BLOCKING TETRODOTOXIN-SENSITIVE SODIUM CHANNELS. ALSO DISCLOSED IS A NOVEL CLASS OF COMPOUNDS | ELAN PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | disclosed |
| US-6166085-A | Method of producing analgesia | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-12-26 | — | — | US | disclosed |
| US-6166085-A | Method of producing analgesia | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0915834-A1 | METHOD AND COMPOSITIONS FOR PRODUCING ANALGESIA | ELAN PHARMACEUTICALS, INC. (US) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998010759-A1 | METHOD OF PRODUCING ANALGESIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1998010759-A1 | METHOD OF PRODUCING ANALGESIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1997033860-A1 | METHOD AND COMPOSITIONS FOR PRODUCING ANALGESIA | NEUREX CORPORATION (US) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165812-A1 | NOCICEPTOR NEURONS CONTROL CANCER IMMUNOSURVEILLANCE | OPRL1, MRGPRX1, RAMP1 | TERT 4437/4885ALDH1A1 2250/4885HTT 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.